A multicenter, prospective, single-arm study of olaparib as maintenance therapy in BRCA wild-type patients with newly diagnosed advanced ovarian, fallopian tube, and primary peritoneal cancer.
Principal Investigator
Dott. Luigi Carlo Turco
Contact Information for Access
Phase
FASE II
Status
ATTIVO
Objective of the study
To describe the efficacy of maintenance therapy with Olaparib and to evaluate the prognostic value of patients’ clinical and biological characteristics and tumor biomarkers in this setting in terms of progression-free survival (PFS).
Gynecologic (ovary, fallopian tubes, peritoneum)
ClinicalTrials.gov ID NCT05233982
Sponsor: National Cancer Institute, Naples
Pathologies
Gynecologic cancers (gynecological tumors)
Medication
Olaparib
Who is eligible to participate in the study?
Patients who are 18 years of age or older and who meet the study’s eligibility criteria may participate in this study.
Patients with a histological diagnosis of high-grade serous or endometrioid epithelial ovarian cancer (including primary peritoneal or fallopian tube cancer) at advanced stage III–IV, who have achieved a complete or partial response to first-line platinum-based therapy, excluding bevacizumab. Documented absence of somatic and germline BRCA1/2 mutations. Sufficient formalin-fixed, paraffin-embedded tumor tissue from surgery must be available for translational analysis.
View the full study Back to search page